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Abstract
The brain is continually reorganizing (plasticity). Plastic changes within the sensori‐
motor system are not only beneficial (adaptive plasticity) but may even worsen function
(maladaptive plasticity). Conditions such as dystonia and poststroke spasticity (PSS)
that interfere with motor performance could be attributed to maladaptive plasticity.
Botulinum toxin (BoNT) has been proven to be safe and effective in treating various
hyperfunctional cholinergic states. Beside the well‐known neuromuscular junction site
of action, BoNT also exerts effects through supraspinal mechanisms and can even affect
cortical  reorganization.  The  hypothesis  of  central  reorganization  following  BoNT
treatment  has  been  supported  by  studies  using  neurophysiological  and  imaging
methods in patients with focal dystonia and PSS. The growing evidence of BoNT‐related
central  (remote)  effects  make BoNT injections a  promising tool  to  favorably affect
maladaptive changes even at the cortical level.
Keywords: stroke, dystonia, spasticity, botulinum toxin, functional magnetic reso‐
nance imaging, neuronal plasticity
1. Introduction
Botulinum toxin (BoNT) type A is a valuable therapeutic option for the management of
poststroke spasticity (PSS) [1–3] and focal  dystonia [4].  BoNT acts at  the neuromuscular
junction, and the mechanism of action on muscle spindles has been well described [5, 6]. In
the  periphery,  BoNT  affects  intrafusal  fibers  as  well  as  extrafusal  ones  and  thus  alters
pathological sensory inputs to the central nervous system (CNS) by blocking of the neuro‐
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muscular junction of the gamma motor neurons [6]. This blockade leads to a reduction of Ia
afferent signals and indirectly inhibits pre‐existing feedback‐driven execution mode. This is
probably the mechanism by which BoNT injected in the periphery may induce dynamic
changes  at  several  hierarchical  levels  of  the  sensorimotor  system,  presumably  including
cerebral cortex [7]. The hypothesis of central reorganization following BoNT treatment has
been supported by studies using neurophysiological and imaging methods in patients with
focal dystonia and PSS.
2. Spasticity
Stroke is a leading cause of disability in Western countries [8]. Ischemic lesions of descending
tracts result in upper motor neuron syndrome (UMNS) comprising both negative signs
(weakness and loss of dexterity) and positive signs (especially spasticity) [9]. Up to two thirds
of stroke survivors experience impaired function and spasticity of the upper limb, and wrist
and finger impairments usually prevail over involvement of proximal shoulder muscles [10,
11]. The degree of muscle weakness is crucial in determining the movement deficit following
stroke, but spasticity may also be contributory [12, 13]. It is generally recognized that PSS may
interfere with voluntary movement [14]. Disabling PSS affects patient’s quality of life and
frequently causes significant reductions in manual dexterity, mobility, walking/falling, and
performance of activities of daily living (ADL) [15]. Disabilities associated with PSS place a
significant burden on stroke survivors and subsequently on caregivers [16]. Prevalence data
for PSS are limited by a lack of population‐based studies; however, current estimates range
from 19 to 42.6% [15, 17]. Numerous clinical trials have shown that BoNT is a safe and effective
therapeutic tool to relieve upper limb PSS and improve function of the affected limb [1, 18,
19]. Recommended treatment strategies to relieve PSS combine physiotherapy procedures
with BoNT application [1–3]. Although BoNT acts primarily on muscle spindles [5, 6], there is
growing evidence that BoNT also exerts effects through supraspinal mechanisms and can even
affect cortical reorganization [7]. The hypothesis of central reorganization following BoNT
treatment has been supported mostly by studies using neurophysiological [20–23] and
imaging [24–26] methods in patients with focal dystonia. Most of published functional
magnetic resonance imaging (fMRI) studies in chronic stroke patients have described changes
in task‐related cortical activity following physiotherapy treatment [27, 28]. In the last decade,
several studies reported central (remote) effects of BoNT in PSS.
Two pilot studies using blood oxygenation level dependent (BOLD) functional magnetic
resonance imaging (fMRI) to register and localize BoNT‐related changes of cerebral cortex
activation were conducted. Both studies showed that effective treatment of spasticity led to a
reduction of abnormal extensive bilateral activation of cortical and subcortical areas during
actively performed or imagery of finger movement. The between‐session contrasts designed
to display the specific BoNT effect revealed a significant change in the local BOLD signal
magnitude not only in traditional motor areas but also in areas that have been considered to
be a part of a “broader” motor system or have only rarely been reported in the context of
volitional motor control (posterior cingulate, DLPFC, Broca’s area). Finally, the above‐
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mentioned studies confirmed that fMRI is a suitable tool in studying cortical relief of spasticity
and that the three‐session study design permits decomposition of BoNT effect from com‐
pounding effects of rehabilitation and time [29, 30]. Nevertheless, the promising results have
been limited by the small number of subjects.
Manganotti et al. [31], in another fMRI study involving patients with PSS treated with BoNT
alone, reported a similar effect representing a trend toward normalization of movement‐
induced brain activation. Detected pretreatment overactivation in the bilateral sensorimotor
cortex (SM1, supplementary motor area (SMA)) and cerebellum was followed by decrease in
extent of sensorimotor activation with increase in laterality after BoNT application.
In a subsequent fMRI study based on the pilot results [29, 30], using the combination of
rehabilitation and BoNT for completely plegic patients with PSS, the alleviation of spasticity
following BoNT treatment was associated with reduction of the brain activation volume in
response to a motor imagery. The BOLD signal at week 11, when peripheral effect of BoNT
was expected to wane (BoNT‐off), revealed further volume reduction (Figure 1). The authors
hypothesized that BoNT application modifies the process of cerebral plasticity and that this
impact might persist despite temporary effect of BoNT on muscle fibers. A notable exception
to this trend would be in regard to the cerebellar hemispheres, which either appear similarly
active across the three imaging sessions (ipsilesional) or manifest transient activation at the
time of maximal BoNT effect (contralesional) [32].
Figure 1. Functional MRI activation during imagery of finger movement (A) before BoNT treatment, (B) 4 and (C) 11
weeks after BoNT application (group mean statistical maps overlaid in color on the MNI anatomical template). Adapt‐
ed with permission from Veverka et al. [32].
The following study of two age‐matched groups with moderate and severe hand weakness
demonstrated different effects of BoNT‐induced improvement in spasticity on sensorimotor
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networks. The plegic group performing movement imagery in MR scanner manifested BoNT‐
induced reduction of activation in structures associated with visual imagery. Regarding the
occipitoparietal changes, the BoNT treatment in plegic subjects might switch their neural
processing from visual to kinesthetic imagery pattern. In the paretic group, performing
sequential finger movement, overall brain activation was markedly reduced after BoNT.
Between‐session contrasts yielded significant BoNT‐related changes in the ipsilesional DLPFC
and Broca’s area, similarly as in the study of Tomášová et al. [30]. Both areas have been reported
to participate in motor learning, rather than volitional motor performance and control [33].
Several areas with decreased task‐related BOLD response after BoNT‐induced spasticity relief
subsequently increased their activation again as BoNT effect waned. These included the
ipsilesional lateral occipital cortex, ipsilesional cortex bordering the intraparietal sulcus, and
contralesional cerebellum. Activation reductions over the whole three‐month study period
were located in bilateral occipital cortex, which may reflect the decreased need to engage
visualization in order to perform the movement with the paretic hand.
Another study using a combination of BoNT and rehabilitation in a subgroup of post‐stroke
spasticity with residual motor activity reported BOLD activity increases in the ipsilesional
primary sensorimotor cortex and in the contralesional secondary somatosensory area 14 weeks
following BoNT application enhanced by three months of repetitive arm cycling. The authors
concluded that observed cortical changes reflect a treatment‐induced effect [34].
In a recent study, Bergfeldt et al. [35] reported an increase in brain activation in response to an
active motor task in the motor and premotor cortex (predominantly contralesional) at the
baseline and an overall decrease in activation with contralesional predominance following
comprehensive focal spasticity therapy.
A more recent study [36] engaging severely affected patients with PSS revealed BoNT‐related
patterns of cerebral cortex activation during passive hand movement. The whole‐brain fMRI
data were acquired during paced repetitive passive movements of the plegic hand (flexion/
extension at the wrist) alternating with rest. Passive movement induces sensorimotor cortex
activation in another way, with particular emphasis on afferent inputs to the CNS [37]. Across
all the sessions, fMRI activation of the ipsilesional sensorimotor cortex (M1, S1, and SMA)
dominated, with notable temporal reduction of activation throughout the study (paired
contrast pre‐BoNT > BoNT‐off). At week 4, when maximal pharmacological effect of BoNT is
expected, additional clusters transiently emerged bilaterally in the cerebellum, in the con‐
tralesional sensorimotor cortex, and in the contralesional occipital cortex. Paired contrasts
demonstrated significant differences post‐BoNT > pre‐BoNT (bilateral cerebellum and
contralesional occipital cortex) and post‐BoNT > BoNT‐off (ipsilesional cerebellum and SMA)
[36].
Stroke triggers a number of processes at various levels of the motor system that can cause
spontaneous recovery or motor improvement (adaptive plasticity). Plastic changes within the
sensorimotor system are not only beneficial but may even worsen residual function. From this
point of view, appearance of poststroke upper limb spasticity that interferes with motor
performance could be attributed to so‐called maladaptive plasticity. The BoNT injection is a
well‐established component of multimodal treatment of PSS. The growing evidence of BoNT‐
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related central (remote) effects makes BoNT a promising tool to favorably affect maladaptive
changes even at the cortical level.
3. Dystonia
BoNT types A and B have been proven to be safe and effective in treating various hyperfunc‐
tional cholinergic states [38, 39]. BoNT is more effective in blocking active neuromuscular
junctions [40]. BoNT disrupts neurotransmission by cleavage of presynaptic vesicle fusion
proteins; SNAP‐25 for BoNT type A and synaptobrevin for BoNT type B [5]. BoNT is currently
considered to be one of the most effective therapeutic options in the management of focal
dystonias [4]. The clinical effect of BoNT on dystonia is assumed to be mediated by dynamic
changes at multiple levels of the sensorimotor system, from the neuromuscular junction up to
the cerebral cortex, as documented by previous behavioral and electrophysiological studies
[21, 41]. Some fMRI studies showed significant treatment‐related changes in the sensorimotor
network in patients with cervical dystonia receiving long‐term treatment with BoNT [25, 26].
It is important to stress here that the BoNT experience from the past 20 years brought us nearer
to our understanding of the underpinnings of current dystonia pathophysiological concepts.
Undoubtedly, the introduction of the first‐generation BoNT products (Botox, Allergan
Pharmaceuticals, Irvine, CA, USA; Dysport, Ipsen Pharmaceutical, Paris, France) not only led
to the breakthrough in dystonia treatment but also the breakthrough in dystonia research. We
now know that the dystonic hyperactive and cholinergically sensitive extrafusal, and in
parallel, the intrafusal muscle fibers are the prime targets of BoNT therapy [6]. It is in the latter
effect of BoNT in muscle spindles that would eventually modify proprioceptive spindle
afferents, as these are partly dependent on the intrafusal muscle fiber tensions. A modification
of the central programs with BoNT may eventually occur at the spinal and supraspinal levels
[6]. Soon, specialists in movement disorders clinics realized that dystonia may behave
differently during the course of BoNT treatment. The first reports described the changes of the
muscular pattern [42–46] that may have implied a central mechanism of dystonia. Studies that
employed the long‐latency reflexes and the central SEP components provided support to such
central mechanisms in dystonia [21], and this would include TMS [22]. Interestingly, the
cortical abnormality in dystonia (either the excitability or intracortical inhibition) changed (i.e.,
“normalized”) following an efficacious treatment with BoNT. The implication was that a
peripheral blockade of effectors may have engaged the central motor programs in dystonia.
As we await more data on the probable “direct” retrograde effects of BoNT, the “indirect”
effects remain tenable to date, the latter being hinged upon the normalization of abnormal
muscle‐spindle functioning in dystonia [6]. The consequent and apparent normalization of the
cortical disorder following BoNT injections in dystonia may indicate that the manipulation of
proprioceptive afferent input has a substantial impact on the disorder directly at the central
level [21, 22]. It can be assumed that the abnormalities of Bereitschaft potentials, contingent
negative variation, and electroencephalogram desynchronization point (with a high level of
probability) to a disorder in the process of motor programming in dystonia and that these
occur at the cortical level. What follows is a defective motor performance, as reflected in
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abnormalities of reciprocal inhibition, long‐latency reflex, cortical excitability, and intracortical
inhibition. Taken together, it would seem that an abnormal sensorimotor integration exists in
dystonia, and this phenomenon has been alluded to in a number of published works [6, 47,
48]. The sensorimotor integration in the physiological perspective involves all parts of the
motor and sensory system, including the motor circuits, in which the basal ganglia and the
premotor and motor cortex are the principal components. Recently, it has been hypothesized
that sensorimotor integration is, in fact, a function of brain plasticity. Indeed, transcranial
stimulation studies have supported the likely occurrence of disordered plasticity in dystonia
[49, 50].
Figure 2. Functional MRI activation during finger movement and simultaneous median nerve stimulation: controls (A),
torticollis patients before BoNT treatment (B), and torticollis patients 4 weeks after BoNT treatment (C); group mean
statistical maps overlaid in color on MNI anatomical template. Adapted with permission from Opavský et al. [25].
Perhaps to date, the most appropriate tool to investigate brain plasticity would be functional
magnetic resonance imaging (fMRI). We have seen the changes that are typical for altered brain
plasticity in torticollis patients (when compared with healthy individuals) and their normali‐
zation following successful treatment with BoNT. Significant reduction of task‐related
activation within the ipsilateral supplementary motor area (SMA) and dorsal premotor cortex
was observed following successful BoNT treatment. There was also a trend in SMA activation
in patients to change lateralization from predominantly ipsilateral to contralateral after BoNT.
BoNT treatment was associated with a significant reduction in finger movement‐induced fMRI
activation (during simultaneous median nerve stimulation) of several brain areas (Figure 2),
especially in SMA, cingulum, contralateral thalamus, secondary somatosensory cortex, and
also in the central part of cerebellum, close to the vermis [25, 26]. These results support previous
observations that the BoNT effect has a correlate at the central nervous system level. It is our
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belief that further studies will show us that the sensorimotor integration or brain plasticity
represents the process of motor preparation itself, even in the expert motor performances.
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